PLX

Protalix BioTherapeutics, Inc. (PLX) ESG Analysis Analysis (2026)

Invetso Score: 7.4/10 — Strong · Last Updated: 2026-08-01

Environmental

PLX appears above many peers on environmental intensity because R&D at 24.7% of revenue supports lower-material, knowledge-based value creation versus more resource-intensive healthcare peers.

The low debt-to-equity ratio of 0.13 can reduce pressure for asset-heavy expansion, which typically limits incremental environmental footprint relative to leveraged peers.

A gross margin near 69.2% is consistent with a less emissions- and waste-intensive operating model than manufacturing-heavy peers, though direct emissions data is not provided.

No disclosed environmental controversies or high-carbon exposure were provided, so the main relative advantage is a structurally lighter operating profile versus peers.

Social

High R&D intensity at 24.7% of revenue suggests sustained investment in product quality and innovation, which generally supports stronger patient and stakeholder outcomes than lower-investing peers.

Stock-based compensation at 2.8% of revenue is modest, indicating less dilution pressure and potentially better alignment than peers with heavier equity-based pay practices.

The absence of provided labor, safety, or product-quality controversies limits downside evidence, leaving PLX’s social profile comparatively stable versus peers.

No peer-specific workforce or access-to-medicine metrics were supplied, so the score reflects a solid but not clearly leading social position.

Governance

Debt-to-equity of 0.13 indicates conservative balance-sheet governance, which usually reduces refinancing risk and discipline concerns versus more levered peers.

Negative net debt to EBITDA of -0.69 suggests net cash, a governance strength because it lowers creditor dependence and financial constraint relative to indebted peers.

Stock-based compensation at 2.8% of revenue appears contained, which can signal more restrained executive dilution than peers with aggressive equity awards.

No evidence of accounting, board, or controversy issues was provided, so governance looks sound but not exceptional versus best-in-class peers.

Overall Score

PLX screens as a strong relative ESG performer versus peers, led by a capital-light profile and conservative leverage, with no provided evidence of material ESG controversy.

Score Driver: Conservative Balance-Sheet Governance Combined With A Capital-Light Operating Model

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Protalix BioTherapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →